The effect of early perindopril administration on mortality and morbidity in patients with high risk of acute myocardial infarction.
The angiotensin-converting enzyme inhibitors (ACEI) therapy reduces mortality and morbidity after acute myocardial infarction (AMI). Though, there are a few questions to face, in what concerns the ACEI therapy: patients selection, starting time and duration of treatment, pharmacological profile of the various ACEI and their therapeutic efficiency. We aimed to determine if early Perindopril administration in AMI, for three months, may decrease mortality and morbidity in selected patients (high risk and streptokinase thrombolysis).
Protopopescu
T
T
Clinic of Cardiology, St. Pantelimon Emergency Clinical Hospital, Bucharest, Romania.
Toporan
D
D
Paraschiv
A
A
Ioan
A
A
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000401:mortality; D010359:Patient Readmission; D020913:Perindopril / Q000008:administration & dosage*; D012189:Retrospective Studies; D012307:Risk Factors; D018709:Statistics, Nonparametric; D013997:Time Factors
D000806:Angiotensin-Converting Enzyme Inhibitors; D020913:Perindopril